Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898203 | 0.91 | CTSK (0.42) | PDE2ACTSKKCNH2MAP4K4DRD2 | |
| SCHEMBL17898200 | 0.84 | PROKR1 (0.45) | KCNH2HRH3 | |
| SCHEMBL20746672 | 0.82 | PDE2A (0.47) | PDE2AMAP4K4HTR1A | |
| SCHEMBL15538759 | 0.81 | PDE2A (0.49) | PDE2AMAP4K4HTR1ACYP2D6HRH1 | |
| SCHEMBL17901759 | 0.73 | SLC6A3 (0.45) | MAP4K4DRD2SLC6A4SLC6A3HRH3 | |
| SCHEMBL17901757 | 0.73 | MAP4K4 (0.46) | MAP4K4DRD2SLC6A4SLC6A3HTR1A | |
| SCHEMBL17898209 | 0.69 | PROKR1 (0.46) | — | |
| SCHEMBL15537231 | 0.67 | PDE2A (0.45) | PDE2AKCNH2DRD2HTR1ACYP2D6 | |
| SCHEMBL17898213 | 0.66 | CYP3A4 (0.53) | PDE2AKCNH2DRD2HTR1AHRH3 | |
| SCHEMBL17898220 | 0.65 | HRH1 (0.45) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | PDE2A 706/4885CTSK 758/4885KCNH2 3811/4885 |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | PDE2A 706/4885CTSK 758/4885KCNH2 3811/4885 |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | PDE2A 706/4885CTSK 758/4885KCNH2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.